Extensive-stage small cell lung cancer (ES-SCLC) is an aggressive disease with a poor prognosis. The recent addition of immunotherapy to the treatment landscape has changed the standard of care for ES-SCLC. In this interactive activity an expert will guide you through the latest evidence on checkpoint inhibitors for the management of ES-SCLC and offer expert insight into effectively and safely incorporating immunotherapy into your practice to improve patient outcomes.
Upon successful completion of this education activity, participants should be better able to:
Associate Professor, Medicine
Assistant Director, Educator Development Program
Clinical Director, Thoracic Oncology Program
Vanderbilt University Medical Center